Bicycle Therapeutics Q2 net loss narrows to $50.3 million from $79.0 million
Bicycle Therapeutics reported a second-quarter 2026 net loss of $50.3 million, or $(0.72) per share, compared with $79.0 million, or $(1.14) per share, a year earlier. Collaboration revenue fell to $629 thousand from $2.9 million, and the company said cash and cash equivalents of $510.1 million give an expected cash runway into 2030.
Key points
- Net loss was $50.3 million, or $(0.72) per share, for the three months ended June 30, 2026, versus $79.0 million, or $(1.14) per share, a year earlier.
- Collaboration revenue was $629 thousand for the quarter, versus $2.9 million in the prior-year quarter.
- R&D expenses were $41.2 million, down from $71.0 million, partly reflecting a workforce reduction announced in March 2026.
- Cash and cash equivalents were $510.1 million at June 30, 2026, versus $628.1 million at December 31, 2025, with expected cash runway into 2030.
The filing
Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 30, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.